SAN JOSE, Calif., - January 20, 2026 - BrightInsight, Inc., the leading global platform for biopharma digital health solutions, today announced the addition of two seasoned commercial leaders to its Executive Leadership Team. Nicole Warshauer has been appointed Vice President, Marketing, and Andrew “AJ” Schultz has joined as Executive Vice President, Sales & Commercial Strategy. Together, they will help biopharma and medtech partners unlock the full commercial and clinical value of digital across global portfolios.
These appointments follow a year of major momentum for BrightInsight, including global launches and expansion of high-impact digital solutions—most notably the Patient App developed in collaboration with Sanofi and their partner, Regeneron, which has demonstrated positive impact on patient treatment adherence and persistence—and a new round of funding to fuel the next phase of growth. The expanded leadership bench reflects BrightInsight’s commitment to pairing proven digital health infrastructure with world-class commercial and marketing expertise for its biopharma customers and investors.
“BrightInsight is at a pivotal inflection point. We have proven that our platform delivers measurable clinical impact, including significant lifts in patient treatment adherence and persistence,” said Kal Patel, MD, CEO and Co-Founder of BrightInsight. “On the heels of our recent product milestones and new funding, we are doubling down on our greatest asset: our people. Strategic hires like Nicole in Marketing and AJ in Sales & Commercial Strategy represent critical investments in the leadership that will help us further define the digital health infrastructure for the world’s largest biopharma companies and their leading brands.”
About the New Appointees
Nicole Warshauer is Vice President of Marketing at BrightInsight, where she leads brand and demand strategy to help global biopharma and medtech partners bring trusted, patient-centered digital solutions to market at scale. With more than 15 years of experience across healthcare, pharma, tech, design, and education, she is known for building full-stack marketing organizations, high-trust brands, and AI-powered marketing engines that convert brand strength into measurable growth. Alongside her role at BrightInsight, she continues to advise and support mission-driven organizations on positioning, content systems, and reputation-building.
Andrew “AJ” Schultz is Executive Vice President, Sales & Commercial Strategy at BrightInsight, where he helps healthcare and life sciences organizations harness digital innovation to deliver more personalized, connected, and patient-centered experiences at scale. With a career focused at the intersection of healthcare, technology, and commercial strategy, he is recognized for turning early-stage concepts into scalable growth engines, building high-performing commercial and product teams, and designing go-to-market models that create durable competitive advantage. Previously, he held senior leadership roles at PatientPoint and AmerisourceBergen (now Cencora), further establishing his track record as a digital health innovator and growth leader.
BrightInsight’s Momentum and Market Position
The addition of Nicole and AJ comes as BrightInsight continues to expand the capabilities of its platform, including the integration of advanced artificial intelligence to power more personalized and predictive interventions. With a strengthened leadership team and a robust balance sheet, BrightInsight is positioned to help its biopharma partners move from fragmented, reactive support models to unified, data-driven patient experiences that scale across brands, indications, and geographies.
About BrightInsight
BrightInsight is a next-generation platform addressing the more than $500B global challenge of patient adherence and persistence. Using a scalable, modular approach, BrightInsight rapidly deploys digital-centric, AI-forward patient support programs that balance centralized infrastructure with decentralized, market-specific execution to advance both global and local brand strategies. The platform is designed to deliver the right intervention, in the right way, at the right time—improving outcomes for patients while driving measurable value for life sciences companies.
Early data with partners such as Sanofi shows a meaningful 10% total improvement in patient adherence compared to existing patient support program and specialty pharmacy models—demonstrating the potential of BrightInsight’s approach, with significant runway ahead.
For more details, visit BrightInsight’s website, Blog, X and LinkedIn pages.
Media contact:
Helen Shik
Shik Communications
Helen@ShikCommunications.com
1.617.510.4373